ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Feb 28, 2014
Thank you…
We can’t begin to tell you how much we appreciate feedback.
Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space .
Dec 20, 2013
Dividend Increases/Decreases for the Week Ending December 20
Let's take a look at dividend increases/decreases for the week ending December 20.
Oct 29, 2013
Pfizer’s and Merck’s 3Q Performance
Let’s take a look at fundamental performance of Pfizer and Merck during the third quarter.
Oct 25, 2013
Surveying 3Q Performance from Big Pharma: Bristol-Myers, Eli Lilly, and AbbVie
Let’s take a look at the third-quarter performance of a few pharmaceutical firms.
Aug 8, 2013
Why Zoetis’ Second Quarter Was Decent
Pfizer spin-off Zoetis serves a niche animal healthcare market.
Aug 5, 2013
Which Sectors Are Leading the Market Higher? And Why Is This Important?
Identifying sector and industry leadership is very important for the institutional money manager as doing so often leads to undervalued firms that are just starting to have their value recognized by the market — Valuentum stocks. Let’s dig into which sectors have been strong and which ones have been weak so far in 2013.
Aug 1, 2013
Pfizer and Merck Show Revenue Declines; Pipelines Remain Strong
Pfizer and Merck faced key patent expirations in the second quarter. However, both of their respective pipelines are promising.
Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015.
Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.